References
- Hamblin T J. Chronic lymphocytic leukaemia. Clin Lab Haematol. 1987; 1: 449–91
- Binet J L, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
- French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of ‘CHOP’ regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; 1: 1346–9
- Keating M J, Hester J P, McCredie K B, et al. Long-term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma 1990; 2: 391–7
- Grever M R, Kopecky K J, Coltman C A, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–9
- Keating M J, Kantarjian H, Talpaz M, et al. Fludarabine therapy in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 461–6
- Cheson B D, Bennett J M, Rai K R, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 1988; 29: 152–63
- Rozman C, Montserrat E, Rodríguez-Fernández J M, et al. Bone marrow histological pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–8
- International Workshop on Chronic Lymphocytic Leukemia. Chronic Lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110: 236–8
- Letwin B W, Wallace P K, Muirhead K A, Hensler G L, Kashatus W H, Horan P K. An improved clonal excess assay using flow cytometry and B-cell gating. Blood 1990; 75: 1178–85
- Johson A, Olofsson T. Flow cytometric clonal excess analysis of peripheral blood, routine handling and pitfalls in interpretation. Cytometry 1993; 14: 188–95
- Pollard P, Owen G, Worwood M. PCR-based immunogenotyping at the Ig heavy chain CDR3 locus: improvements in resolution. Br J Haematol. 1993; 84: 169–71
- Brugiatelli M, Callea V, Morabito F, et al. Immunological and molecular evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical remission phase. Cancer 1989; 63: 1979–84
- Jaksic B, Brugiatelli M. For the International Society of Chemo-Immunotherapy (IGCI, Vienna) CLL Study Group. High dose continuous chlorambucil vs. intermittent chlorambucil plus prednisone for treatment of B-CLL. IGCI CLL-01 trial designed and evaluated by total tumour mass (TTM) and survival. Chronic Lymphocytic Leukemia; Recent progress and future direction 1987; 329–36
- Vuillier F, Claisse J F, Vandenvelde C, et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195–204
- Robertson L E, Hu Y O, Butler J J, et al. Response assessment in chronic lymphocytic leukemia after Fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29–36